Treatment with Lyxumia, when added to basal insulin, resulted in a significant reduction in HbA1c levels compared to placebo. ...more...
Fero Industries Successfully Completes Sucanon® Type-2 Diabetes Human Clinical Trials in the Middle East
Fero Industries, Inc. is pleased to announce that independent human clinical trials of Sucanon® have been successfully completed in the Middle East.  The results of the clinical trials conducted at the University of Tehran in Iran have confirmed previous studies from Canada, China, and Peru, which show Sucanon® to be a safe and effective treatment for Type-2 diabetes and pre-diabetes. Â. ...more...
MannKind Corporation (Nasdaq: MNKD) , focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011 at 4:00 PM (ET) in New York. ...more...
Participants sought for study on new diabetes drug
Meg Farris / Eyewitness News Medical Reporter METAIRIE, La. -- Diabetes has very severe consequences. It can damage your vision, your heart, and even your sexual function. Doctors say it is crucial to get your blood sugar under control so less damage is done to your body. Now a treatment is proving to be better than what is on the market already and local diabetics can be part of the free. ...more...
Link between environment and genetics in triggering multiple sclerosis: Discovery points to personalized treatments
Environmental and inherited risk factors associated with multiple sclerosis -- previously poorly understood and not known to be connected -- converge to alter a critical cellular function linked to the chronic neurologic disease, researchers have discovered. ...more...
Diabetes Patients May Have Higher Fracture Risk
Older people with type 2 diabetes may have a higher risk for fractures that those without diabetes, even though they tend to have less bone density loss as measured by bone mineral density testing. ...more...
MannKind to Present at the Jefferies 2011 Global Healthcare Conference
MannKind Corporation , focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011 at 4:00 PM in New York. ...more...
'Ultra-bad' cholesterol increases risk of heart disease in people with type 2 diabetes
Scientists from the University of Warwick have discovered why a newly found form of cholesterol seems to be 'ultra-bad', leading to increased risk of heart disease. The discovery could lead to new treatments to prevent heart disease particularly in people with type 2 diabetes and the elderly. ...more...
Earlier And More Accurate Prediction Of Diseases Such As Diabetes, Atherosclerosis And Heart Disease, Presented At ...
Studying the genetic make-up of different varieties of lipids (fatty molecules) in the blood plasma of an individual can lead to a better and earlier prediction of diseases such as diabetes, atherosclerosis, and heart disease, two researchers will tell the annual conference of the European Society of Human Genetics today (Monday 30 May). In the first study, Dr... ...more...
No comments:
Post a Comment